The EPS beat is entirely from non-recurring Takeda license revenue, not operational improvement. Monitor upcoming Phase 2 rinvatercept data in H1 2027 and any further Takeda milestones or partnership developments.
Drugs in focus
KROS drug pipeline →rinvatercept
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.
Price Chart
Executive Summary
Keros Therapeutics reported Q3 2026 net income of $14.2 million, a significant swing from a net loss of $7.3 million in Q3 2025, driven by $40 million in license revenue from Takeda. GAAP diluted EPS was $0.70, far above the consensus estimate of -$0.86, but the beat is entirely due to non-recurring license revenue. The company's cash runway extends into H2 2028, and it dosed the first patient in a Phase 2 trial of rinvatercept for DMD.
Key Financial Metrics
Key Facts
- Q3 2026 net income of $14.2 million vs net loss of $7.3 million in Q3 2025
- GAAP diluted EPS of $0.70 vs consensus estimate of -$0.86
- $40 million in license revenue from Takeda drove the swing to profitability
- Research and development expenses $20.5 million, up from $19.5 million
- General and administrative expenses $6.7 million, down from $10.1 million
- Cash and cash equivalents $259.5 million as of September 30, 2026
- Cash runway expected into the second half of 2028
- First patient dosed in Phase 2 trial of rinvatercept for DMD in September 2026
- Nominated KER-206, a nonclinical ligand trap for bone remodeling
Financial Impact
Net income of $14.2 million vs net loss of $7.3 million; GAAP diluted EPS $0.70 vs consensus -$0.86; $40M license revenue from Takeda
Risk Factors
- EPS beat is entirely non-recurring license revenue, not sustainable
- Company remains in net loss position on a trailing nine-month basis ($38.3M loss)
- Clinical-stage biotech with no approved products; pipeline execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397005 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers